SCHEMBL23755331

SCHEMBL23755331

Clc1cc(N2CCOCC2)c2[nH]ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.47
MTOR P42345 4/20 0.47
MAPT P10636 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
NCF1 P14598 2/20 0.43
LRRK2 Q5S007 3/20 0.42
CHEK1 O14757 2/20 0.42
AURKA O14965 2/20 0.42
JAK2 O60674 2/20 0.42
MAP4K4 O95819 2/20 0.42
PAK4 O96013 2/20 0.42
ABL1 P00519 2/20 0.42
CSF1R P07333 2/20 0.42
RET P07949 2/20 0.42
LTK P29376 2/20 0.42
KDR P35968 2/20 0.42
MAPK8 P45983 2/20 0.42
MAPK9 P45984 2/20 0.42
RPS6KA3 P51812 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30993430 0.78 GAA (0.43) PIK3CAMTORMAPTNCF1LRRK2
SCHEMBL23773829 0.77 KMT2A (0.42) MAPTCYP1A2CYP2D6NCF1GAA
SCHEMBL16094377 0.77 PIK3CA (0.56) PIK3CAMTORMAPTCHEK1JAK3
SCHEMBL4733419 0.75 NCF1 (0.74) MAPTNCF1GAASMN1; SMN2KMT2A
SCHEMBL2814765 0.74 NCF1 (0.50) PIK3CAMAPTCYP1A2CYP2D6NCF1
SCHEMBL31283928 0.73 MAPT (0.47) PIK3CAMAPTCYP1A2CYP2D6NCF1
SCHEMBL24776296 0.73 MAPT (0.47) PIK3CAMAPTCYP1A2CYP2D6NCF1
SCHEMBL25390232 0.72 PIK3CA (0.55) PIK3CAMTORMAPTCYP1A2CYP2D6
SCHEMBL25391511 0.71 PIK3CA (0.46) PIK3CAMTORMAPTCYP1A2CYP2D6
SCHEMBL16094338 0.71 PIK3CA (0.59) PIK3CAMTORMAPTCHEK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
EP-4103281-A1 PIKFYVE KINASE INHIBITORS Acurastem Inc. (US) 2022-12-21 EP disclosed
WO-2021163727-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated (US) 2021-08-19 WO disclosed
WO-2021163727-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated (US) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135152-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIP5K1C PIK3CA 9/4885MTOR 195/4885MAPT 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.